reports
Justem Co Ltd: 1 director
A director at Justem Co Ltd sold 51,700 shares at 13,506.000KRW and the significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Melco International Development: 1 director
A director at Melco International Development bought 1,100,000 shares at 6.424HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Parkland Corp: 1 director
A director at Parkland Corp bought 2,000 shares at 40.140CAD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
uniQure Announces First Quarter 2024 Financial Results and Highlights ...
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress ~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 2...
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operations for foreseeable futureMan...
Eledon Announces Clinical Progress with Tegoprubart in the Prevention ...
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the first participant in an investigator-led clinical ...
The Joint Corp. to Participate in Upcoming Investor Conferences
The Joint Corp. to Participate in Upcoming Investor Conferences SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation’s largest provider of chiropractic care through The Joint Chiropractic® network, announced that President and Chief Executive Officer Peter Holt and Chief Financial Officer Jake Singleton are scheduled to participate in the following upcoming conferences: 24th Annual B. Riley Institutional Investor Conference in Beverly Hills, CA Thursday, May 23Roundtable conversation at 1:45 pm PTOne-on-one meetings all day Oppenhei...
SES’s O3b mPOWER System Launches Service via Gilat’s SkyEdge IV Platfo...
SES’s O3b mPOWER System Launches Service via Gilat’s SkyEdge IV Platform SkyEdge IV – the industry’s first MEO-GEO system – enables O3b mPOWER software-driven constellation to deliver services with unparalleled flexibility and scale PETAH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that its SkyEdge IV platform is enabling SES’s O3b mPOWER System to deliver high-performance connectivity services. SkyEdge IV is Gilat’s next-generat...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and ...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader Operational leadership capabilities further strengthened by recent hires Chief Business Officer Sean Brusky and Senior Vice President, Investor Relations Robert Doody Current cash runway ...
Teledyne FLIR Defense Unveils Rogue 1 Loitering Munition System at SOF...
TAMPA, Fla.--(BUSINESS WIRE)-- Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), is introducing its new Rogue 1™ loitering munition system at this week’s Special Operations Forces (SOF) Week convention in Tampa. This press release features multimedia. View the full release here: Teledyne FLIR Defense introduced its new Rogue 1™ loitering munition system at this week’s SOF Week convention in Tampa. Rogue 1 is a next-generation, rapidly deployed, and optionally-lethal vertical takeoff and landing (VTOL) small unmanned aerial system (sUAS) that enables warfighters to ...
First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Re...
First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Results Total revenues increased 14.7%; same-restaurant sales growth of 0.5%*Income from operations margin of 5.1% and restaurant level operating profit margin of 20.8%Net income of $7.2 million and Adjusted EBITDA of $28.6 million9 system-wide restaurants opened across 8 states BRADENTON, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for...
BioCryst to Present at Upcoming Investor Conferences
BioCryst to Present at Upcoming Investor Conferences RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present at the following conferences: Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET. 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET. Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET. H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday...
Meritage Homes Announces Pricing of Convertible Senior Notes
Meritage Homes Announces Pricing of Convertible Senior Notes SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, “Meritage” or the “Company”), the fifth-largest homebuilder in the U.S., today announced the pricing of $500 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2028 (the “notes”). The Company also granted the initial purchasers of the notes a 13-day option to purchase up to $75 million of aggregate principal amount of additional notes. The sale of the notes is expected to settle on May 9, 2024, subject to customar...
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society ...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corp...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for up to $1.01 ...
Enthusiast Gaming to Announce First Quarter 2024 Results on May 15, 20...
Enthusiast Gaming to Announce First Quarter 2024 Results on May 15, 2024 LOS ANGELES, May 07, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX:EGLX) will report financial and operating results for its first quarter ending March 31, 2024, on Wednesday, May 15, 2024, after the market closes. Management will host a conference call and webcast that same day at 5:00 p.m. ET. Conference call details: Toll Free: 1-855-239-1101 (Conference ID: 10189020)Live Webcast: A replay of the webcast will be available on the Investor Relations page of ...
Neumora Therapeutics Reports First Quarter 2024 Financial Results and ...
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multi...
Cipher Mining Provides First Quarter 2024 Business Update
Cipher Mining Provides First Quarter 2024 Business Update First Quarter 2024 GAAP Net Income of $40m, and Non-GAAP Adjusted Earnings of $63m First Quarter 2024 Revenues of $48m Current Self-Mining Hash Rate of ~7.7 EH/s and on track to reach ~9.3 EH/s by end of Third Quarter 2024, with plans to grow to ~25.1 EH/s by end of 2025 NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced results for its first quarter ended March 31, 2024, with an update on its operations and deployment strategy. “We are delighted to announce results for the fi...
American Shared Hospital Services Announces First Quarter 2024 Earning...
American Shared Hospital Services Announces First Quarter 2024 Earnings Conference Call SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its first quarter 2024 financial results on Tuesday, May 14th at 4:30 pm ET / 1:30 pm PT. The first quarter 2024 financial results press release will be issued at the market close...
CI Global Asset Management Launches Actively Managed Artificial Intell...
TORONTO--(BUSINESS WIRE)-- (“CI GAM”) announces that CI Global Artificial Intelligence ETF (“CIAI”) has closed its initial offering of ETF C$ Series Units and begins trading today on the Toronto Stock Exchange under the ticker CIAI. CI GAM is also reducing the management fee of CIAI to 0.20% from 0.55% until the earlier of one year after launch or until CIAI reaches $1 billion in assets under management. As a result of the fee waiver, CIAI will begin trading with the lowest management fee of any artificial intelligence-focused ETF in the Canadian marketplace. The investment objective of C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.